At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. [electronic resource]
Producer: 20110527Description: 1247-51 p. digitalISSN:- 1527-7755
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bevacizumab
- Carboplatin -- administration & dosage
- Chemotherapy, Adjuvant
- Computer Simulation
- Cost-Benefit Analysis
- Disease-Free Survival
- Drug Costs
- Female
- Humans
- Intestinal Perforation -- economics
- Models, Economic
- Neoplasm Staging
- Ovarian Neoplasms -- drug therapy
- Paclitaxel -- administration & dosage
- Randomized Controlled Trials as Topic
- Survival Analysis
- Survival Rate
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Webcast
There are no comments on this title.
Log in to your account to post a comment.